An observational study in Eating Disorders in Adolescence and Eating Disorders in Children, sponsored by Esther Nova. Recruiting at 2 sites in Spain. Open to participants aged 7 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Esther Nova · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Feeding and Eating Disorders with a site in Spain — 10 open to participants now, 11 under way, none of them phase 3. Feeding and Eating Disorders · Spain.
Among the 28 studies in Feeding and Eating Disorders with a site in Spain, this one is one of 3 that started in 2024, is one of 5 observational ones, reaches primary completion later than 5 of the 10 other live ones, and was the 20th registered.
645 studies on the registry are indexed under Feeding and Eating Disorders; 151 are open to participants now.
Browse Feeding and Eating Disorders studies →10 of the 28 studies in Feeding and Eating Disorders with a site in Spain are open now. Recruiting first, the newest first:
Universitat Internacional de Catalunya · Sites in Spain
Ages 13–35 · Healthy volunteers
Universitat Autonoma de Barcelona · Sites in Spain
Ages 18–65 · Women only
Servicio Canario de Salud · Sites in Spain
Ages 10–13
Fundació Sant Joan de Déu · Sites in Spain
Ages 12–17
University of Barcelona · Sites in Spain
Ages 18–65 · Women only · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 99 Feeding and Eating Disorders studies recruiting now, 31 (31%) set no upper age limit and 66 (67%) stop at 75 or younger; 45 take children under 18; 20 take healthy volunteers.
This study: 7 Years to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 158 is above the median of 102 across 177 observational studies indexed under Feeding and Eating Disorders.
Median enrollment 103 across the 23 interventional studies, 135 across the 5 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 28 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Esther Nova as lead sponsor.
Esther Nova has 1 study filed under Feeding and Eating Disorders — fewer than ten, so there is no comparison to draw.
4 of the studies in Feeding and Eating Disorders with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07066033Esther NovaA Study of the Intestinal Microbiota in Children and Adolescents With Eating Disorders. A Perspective From Psychoneuroimmunology | 2026-12 |
| NCT07585955University of ValenciaFamily Connections Transdiagnostic for Relatives of People With Emotional Dysregulation | 2026-12-25 |
| NCT07565129Universitat Internacional de CatalunyaPrevED MR. Improving Emotion Dysregulation Through Mixed Reality Based Dialectical Behavioral Therapy in Adolescents and Young Adults at Risk of Developing Eating Disorders. | 2027-03 |
| NCT07894978Universitat Autonoma de BarcelonaExpand Your Horizon-Spanish | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 28 studies in Feeding and Eating Disorders with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn if behavioral and psychological factors are associated with the intestinal microbiota composition and function in children and adolescents with eating disorders (ED). The main questions it aims to answer are:
Participants with ED will fill in different lifestyle questionnaires and psychological tests; they will also undergo anthropometrical measurements and will provide fecal and blood samples at baseline and one year later. Healthy participants will provide the same lifestyle information, anthopometrical measurements and stool and blood samples. They will only undergo the baseline evaluation.
BACKGROUND: Eating disorders (ED) are severe and complex psychiatric pathologies characterised by the presence of abnormal eating patterns. There is not an easy cure, the clinical courses are long and often present medical, psychiatric and family complications that influence their evolution and prognosis. Almost half of the patients continue with symptoms many years after their first episode. So far, the etiology of AN remains unclear but it certainly seems to encompass multiple intertwined genetic and environmental factors, that seem to affect appetite, behavioral pathways, psychological traits and hypothalamic-pituitary-adrenal (HPA) axis dysregulation. Socio-cultural and familiar factors may favor the onset of an ED. More specifically, there are hypotheses involving brain neurotransmitters and dysregulation of reward systems, via pathways in which the gut-brain axis may be involved. The gut microbiota synthesizes or regulates the production of short-chain fatty acids (SCFAs), bile acids, tryptophan metabolites, and various neurotransmitters and hormones that may affect the central nervous system.
AIM: the study investigates whether the composition and function of the intestinal microbiota in children and adolescents with eating disorders are different from those of healthy children and adolescents. Secondarily, the relationship between the dietary pattern prior to enrollment, the psychopathology symptoms and the intestinal microbiota will be assessed.
STUDY DESIGN: a cross-sectional controlled study will be performed where the microbiota of children and adolescents with ED (AN any subtype or ARFID) will be compared with that of healthy participants matched by sex and age.
SUBJECTS: All patients referred to the specialized ED unit of the Hospital Infantil Universitario Niño Jesús that fulfill inclusion and exclusion criteria and who are willing to participate will be included. Diagnosis will be performed by psychiatrists with DSM-5 criteria.
The following information will be gathered during the interview: i) developmental history, ii) medical and psychiatric history, iii) Behaviors around the ED, iv) psychopharmacological treatment, v) sleep quality and quantity.
Healthy children and adolescents matched by sex and age will be included used as control group, who will be enrolled at their education centers.
BIOMARKER ANALYSES:
PSYCHOMETRIC TESTS: aiming the assessment of i) ED specific psychopathology (EDI-II) ii) comorbidities (anxiety and depression), iii) personality, iv) stressful life events. The family will also fill in i) ED symptoms, ii) care giver experience, iii) parental functioning.
DIETARY STUDY: includes i) 24-hour recall, ii) food frequency questionnaire over the last 15 days and iii) questionnaire on dietary habits. Dietary patterns and diet quality indexes will be derived.
STOOL PROCESSING: Stool samples, at least the size of a walnut are stored at -80C until different aliquots are separated and weighed into processing tubes for the different techniques. For fecal microbiota composition analysis specimens are analyzed as follows: bacterial DNA extraction with chromatographic column and a prior optimization step, shot-gun Illumina DNA sequencing, generation of Operational Taxonomic Unit (OTU) tables at different taxonomic levels, functional gene annotation. The DNA purification is done at the Institute of Food Science, Technology and Nutrition, CSIC and the shot-gun sequencing and bioinformatic analysis at the Microbiological Unit of the Hospital Ramón y Cajal, Madrid, Spain.
SAMPLE SIZE: previous data on microbiota in the pediatric population with ED are lacking as well as those of healthy children from the reference population. The sample size calculation performed was based on an expected effect of moderate-large size according to published findings comparing AN patients and healthy women microbiota and SCFA. For the current study to prove a medium effect size (d=0.45) in the microbiota variables with a confidence level 95% and power 80%, the result was 79 subjects per group. The ex-post power of the differences observed will be calculated.
STATISTICAL METHODS: To identify significant and predictive factors among psychological, clinical and biological variables studied, multivariate predictive models will be run on the different outcomes: binary and multidimensional. The predictive models will be chosen according to the statistical restrictions of the data.
ONE YEAR FOLLOW UP ASSESSMENT: one year after entering the study, participating patients, only, will be evaluated with the same procedures as in the baseline study to check the differences in microbiota composition with time and study potentially prognostic factors.
ETHICS: The study is approved by the Research Ethics Committee at the Hospital Infantil Universitario Niño Jesús (reference number: 0068/23. 28 November 2023) and the Ethics Committee at the Spanish National Research Council (CSIC) (reference number: 245/2023. 22 January 2024). All sensitive information of personal or biological origin will be treated with confidentiality and according to the Spanish law. All biological specimens will be treated according to specified storage, reutilization and discarding procedures as consented by the participating subjects or their legal representatives.
PERSPECTIVES: The results and findings derived from this study will help understand whether the intestinal microbiota contributes to AN etiopathology and might provide evidence to support treatment strategies for personalized treatments and better disease prognosis.
All patients will be recruited in the ED specialized unit of the Niño Jesus University Children Hospital (NJUCH) after receiving a DSM-V ED diagnosis by an experienced psychiatrist. Patients will be eligible on treatment modalities including hospitalization, outpatient consultations or home hospitalization.
The control group will be recruited among healthy children and adolescents attending eligible levels in private and public centers of formal education. Eligible educational centers are those located in geographical areas included in the administrative health zones assigned to the NJUCH. A combination of private and public schools from both metropolitan and peripheral cities is being selected. Invitation letters are sent to the head of the schools and following acceptance, randomization of age levels across schools is performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children and adolescents with a recent onset eating disorder initiating treatment in a Specialized Eating Disorder Unit
Healthy children and adolescents matched by age and sex with the ED patients
Intestinal microbiota composition
Intestinal microbiota composition as derived from Shot-gun metagenomics with deep-sequencing analysis will be used on stool isolated DNA.
Time frame: Baseline
Intestinal microbiota function
Microbial metabolites will be analyzed in fecal water, including SCFA by gas chromatography-FID and aminoacids and neurotransmitters (GABA, dopamine, serotonin) by HPLC.
Time frame: Baseline
Hematology
White blood cells (WBC) and differential.
Time frame: baseline
Routine biochemistry
Glucose, hepatic enzymes (GOT, GPT, gamma-GT), urea, creatinine, uric acid, total bilirubin; C-reactive protein, lipid profile (Cholesterol, HDL-cho, LDL-cho, VLDL-cho).
Time frame: Baseline
Hormones, gastrointestinal and adipose tissue peptides
Insulin, Cortisol, Leptin, active Ghrelin, Total PYY, active GLP-1; and Adiponectin.
Time frame: Baseline
Systemic Inflammation
plasma inflammatory cytokines (MCP-1, IL-2; IL-1beta, IL-6, TNF-alfa; IL-10); markers of intestinal permeability mediators of inflammation, such as LPS-binding protein (LPB) and zonulin-1.
Time frame: Baseline
Change from baseline in fecal microbial taxa quantified by shotgun metagenomics with deep sequencing analysis
In participating patients a second stool sample with be collected after one year of treatment in order to compare data on microbiota composition with baseline results.
Time frame: Baseline and 12 months
Plan to share: Yes — Dataset (xls or csv format) with pseudanonymization including: demographic and socioeconomic variables, diagnostic data, blood and fecal biomarkers, body composition parameters, symptoms and psychological test scores. Metagenomic sequencing FASTQ files obtained from human fecal samples
Supporting information: Study protocol
Time frame: Beginning after publication with no end date
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Feeding and Eating Disorders →